Genscript Biotech Corporation announced appointment of Ms. Shao Weihui as a rotating chief executive officer of the Company with effect from January 1, 2023, and she will be on duty on yearly basis with effect from such date, subject to rotation on yearly basis. Dr. Liu Zhenyu, current rotating chief executive officer of the Company on duty, will complete his term of duty on December 31, 2022. He will remain as a rotating chief executive officer of the Company.

Ms. Shao Weihui, aged 42, has been the chief operating officer of the Company since July 2021 and has been primarily responsible for the operational functions of the Company, including human resources, supply chain, engineering and instrument, information technology, quality and environmental, health and safety functions. She was appointed as member of the Sanctions Risk Control Committee of the Board in March 2022. Ms. Shao has over 16 years of management experience in the life science and biologics development industry.

Ms. Shao joined the Group in July 2005. From July 2005 to April 2017, Ms. Shao served in several positions at the Group, including as a group leader of antibody department, a department head of antibody development and a vice president of reagent service production center. From April 2017 to April 2019, Ms. Shao worked as the deputy general manager of the reagent service business unit.

From April 2019 to August 2020, Ms. Shao served as the president of life science group. From August 2020 to February 2021, she worked as the president of European division of the Company. From February 2021 to July 2021, she worked as the China president concurrently as the general manager of Nanjing site of the Company.

Ms. Shao is currently the chairman of the board of directors of Nanjing Bestzyme Biotech Co. Ltd., the executive director of Jinan Bestzyme Biotech Co. Ltd. and a director of Nanjing Precision Biotechnology Co.

Ltd. She is also the general manager of Nanjing GenScript Biotech Co. Ltd. and the responsible representative of Nanjing GenScript Biotech Co. Ltd. Shanghai Branch.

Ms. Shao obtained her Bachelor of Science degree in biology from Nanjing Normal University in the PRC in June 2002 and a Master of Agriculture Science degree in preventive veterinary from Yangzhou University in the PRC in June 2005. Ms. Shao will hold office of a rotating chief executive officer on duty of the Company for an initial term of one year commencing from 1 January 2023, and is subject to rotation on yearly basis. She will be entitled to receive a fixed annual emolument of RMB2,406,000 and discretionary bonuses of approximately RMB1,600,000 pegged to her performance and the Company's operating performance.

Her emoluments has been determined by the remuneration committee of the Company and approved by the Board with reference to the Company's standards for emoluments, her job responsibilities, the prevailing market conditions and the Company's operating performance and profitability. As at the date of this announcement, Ms. Shao is interested in 2,544,531 underlying shares of the Company in respect of the options and the restricted share awards granted by the Company, representing approximately 0.12% of the issued ordinary share capital of the Company. Save as disclosed above, as at the date of this announcement, Ms. Shao (i) did not hold any position with the Company or other members of the Group, (ii) did not have any interest in the Company or its associated corporation(s) within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), (iii) was independent from and not related to any other Directors, members of senior management, substantial Shareholders or controlling Shareholders (as defined in the Listing Rules, and (iv) had not held any directorship in any listed companies in the last three years preceding the date of this announcement or any other major appointments and professional qualification.

Save as disclosed above, there are no other matters relating to the appointment of her as a rotating chief executive officer of the Company that needs to be brought to the attention of the Shareholders and there is no other information which is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.